Carl Zeiss Meditec’s re-rating journey should continue further
21/02/24 -"Despite our near-term estimates being slightly moderated due to the destocking of consumables and anticipated impact from volume-based procurement headwinds, our target price resets higher by c.4%, ..."
Pages
63
Language
English
Published on
21/02/24
You may also be interested by these reports :
13/08/26
Ottobock continues to deliver, with a strong set of results in 1H26. Core revenues grew by +7.7% (organic +6.7%), largely supported by a strong EMEA ...
12/08/26
Demant reported better-than-expected Q2 results, with robust top-line growth across all segments. Profitability rose by double digits in H1, and ...
12/08/26
Over the past few years, hearing aid firms have disappointed the shareholders who have supported them, resulting in a heavy price being paid. ...
11/08/26
The Q2 results exceeded the street’s expectations, backed by a healthy uptake of newly launched equipment, intra-ocular lenses and dry eye products, ...